
Slightly more than one of every 10 patients with moderate-to-severe kidney disease who undergo coronary angiography enhanced with iopamidol or iodixinol contrast media will die or experience another major adverse event, such as stroke or myocardial infarction, in the year following imaging because of contrast-induced nephropathy (CIN) associated with the procedure.







